Skip to main content
. 2013 Nov 7;306(1):G72–G80. doi: 10.1152/ajpgi.00178.2013

Fig. 7.

Fig. 7.

Effects of sorafenib on pulmonary alterations of HPS. Graphical summaries of alveolar-arterial oxygen gradient (A-aPo2) and microsphere assessment of intrapulmonary shunting after CBDL. Values are expressed as means ± SE (n = 8 animals for each group). *P < 0.05 compared with sham. ‡P < 0.05 compared with CBDL.